No matter what your ASCO program choices, attendees are destined like a modern day Sisyphus to walk the bridge repeatedly as your schedule takes you from one end of McCormick Place to the other.
I am looking forward to the new data expected at the meeting. For diehards who are at ASCO till the last day, next Tuesday will see Dr Chris Parker present updated data on the ALSYMPCA trial for radium-223 (Alpharadin) in advanced prostate cancer. We can expect to see an increase in overall survival (OS) from the 2.8 months presented in Stockholm last year. HT @BiotechStockRsr.
An increase in OS is not uncommon with time, the COU-AA-301 trial results for abiraterone acetate (Zytiga) increased from 3.9 months when initially presented, to 4.6 months at ASCO 2011 last year.
And for those for whom the official ASCO 2012 program is not enough, there’s a series of ancillary events most evenings ranging from an unofficial tweet up to investor presentations, faculty parties and CME events.
The unofficial tweetup hosted by @adamfeurstein and others will be at the Hubbard Inn this Friday from 6pm to 8pm. Last year it featured an eclectic mix of MDs, analysts, investors, Pharma/Biotech peeps, cancer advocates, science bloggers, journalists and PR mavens. Welcome to the world of twitter – @3NT will see you there!